For recurrent respiratory papillomatosis (RRP), novel gene therapy to jump-start immunity to the human papillomavirus (HPV) that causes it was safe and yielded complete response in many cases ...

The FDA has accepted for Priority Review the BLA for PRGN-2012 for the treatment of adults with recurrent respiratory papillomatosis.

For papillomas of the skin, where HPV is known to be the cause ... This causes a rare condition known as recurrent respiratory papillomatosis, which occurs mostly in children.

PRGN-2012 is designed to elicit immune responses directed against cells infected with human papillomavirus, or HPV, 6 or HPV 11. PRGN-2012 received Breakthrough Therapy Designation, Orphan Drug ...

Precigen has won U.S. Food and Drug Administration priority review for its application seeking approval of its proposed PRGN-2012 gene therapy for adults with recurrent respiratory papillomatosis ...

The clinical-stage company, which is advancing a gene therapy to treat a rare disease called recurrent respiratory papillomatosis ... human papillomavirus, or HPV, can cause benign tumors on ...

for the treatment of adults with recurrent respiratory papillomatosis (RRP). RRP is a rare neoplastic disease caused by an infection with human papillomavirus (HPV) 6 or 11. It is characterized by ...